Conor Kilroy Sells 7,162 Shares of Aura Biosciences, Inc. (NASDAQ:AURA) Stock

Aura Biosciences, Inc. (NASDAQ:AURA) insider Conor Kilroy sold 7,162 shares of Aura Biosciences stock in a transaction on Wednesday, April 16th. The stock was sold at an average price of $5.49, for a total transaction of $39,319.38. Following the transaction, the insider now directly owns 179,313 shares in the company, valued at $984,428.37. This represents a 3.84 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Aura Biosciences Trading Down 0.7 %

NASDAQ:AURA opened at $5.36 on Friday. The firm’s 50 day moving average is $6.76 and its 200 day moving average is $8.18. Aura Biosciences, Inc. has a 12 month low of $4.84 and a 12 month high of $12.38. The stock has a market capitalization of $269.21 million, a PE ratio of -3.10 and a beta of 0.43.

Aura Biosciences (NASDAQ:AURA) last issued its quarterly earnings results on Monday, March 24th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.09). Research analysts predict that Aura Biosciences, Inc. will post -1.66 earnings per share for the current year.

Analyst Ratings Changes

AURA has been the topic of several analyst reports. Lifesci Capital upgraded shares of Aura Biosciences to a “strong-buy” rating in a report on Friday, January 31st. HC Wainwright set a $25.00 price target on Aura Biosciences in a research report on Tuesday, March 25th. Citigroup reiterated an “outperform” rating on shares of Aura Biosciences in a report on Wednesday, March 26th. Finally, JMP Securities set a $19.00 target price on Aura Biosciences in a research report on Wednesday, March 26th. Six investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $22.75.

Institutional Investors Weigh In On Aura Biosciences

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Long Focus Capital Management LLC lifted its holdings in Aura Biosciences by 123.9% during the 4th quarter. Long Focus Capital Management LLC now owns 2,537,774 shares of the company’s stock worth $20,861,000 after purchasing an additional 1,404,228 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Aura Biosciences by 6.2% during the fourth quarter. Vanguard Group Inc. now owns 1,917,730 shares of the company’s stock valued at $15,764,000 after buying an additional 112,296 shares during the period. Franklin Resources Inc. lifted its holdings in shares of Aura Biosciences by 3.2% in the fourth quarter. Franklin Resources Inc. now owns 1,723,063 shares of the company’s stock worth $14,164,000 after buying an additional 54,103 shares in the last quarter. Levin Capital Strategies L.P. boosted its position in shares of Aura Biosciences by 169.1% in the fourth quarter. Levin Capital Strategies L.P. now owns 1,247,619 shares of the company’s stock valued at $10,255,000 after acquiring an additional 783,984 shares during the period. Finally, Geode Capital Management LLC grew its stake in Aura Biosciences by 0.4% during the fourth quarter. Geode Capital Management LLC now owns 1,012,799 shares of the company’s stock valued at $8,327,000 after acquiring an additional 3,972 shares in the last quarter. Institutional investors own 96.75% of the company’s stock.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.